Brightcove And 2 Other Penny Stocks Insiders Are Buying

The Dow Jones closed higher by more than 500 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Brightcove

• The Trade: Brightcove Inc. BCOV 10% owner Jonathan Brolin acquired a total 10,000 shares an average price of $3.85. To acquire these shares, it cost around $38.49 thousand.
• What’s Happening: Rosenblatt reiterated Brightcove with a Buy and maintained a $10 price target.
• What Brightcove Does: Brightcove Inc is a provider of cloud-based services for the video ecosystem. The firm targets its solutions at media companies, broadcasters, publishers, and corporations.

Athena Gold

• The Trade: Athena Gold Corporation AHNR 10% owner John D Gibbs acquired a total of 1,428,571 shares at an average price of $0.05. The insider spent around $74.29 thousand to buy those shares. The company’s President and CEO also acquired the company’s shares.
• What’s Happening: Athena Gold closed a non-brokered private placement for gross proceeds of CAD $1,015,000 comprised of 14,500,000 units at a price of CAD $0.07 per Unit.
• What Athena Gold Does: Athena Gold Corp is focused on the exploration and development of precious metals in the Western United States. Its core holding is Excelsior Springs Project in Nevada's Walker Lane Gold District.

Avalo Therapeutics

• The Trade: Avalo Therapeutics, Inc. AVTX 10% owner Caissa Capital Management Ltd acquired a total of 7,500 shares at an average price of $2.99. To acquire these shares, it cost around $22.42 thousand.
• What’s Happening: Avalo Therapeutics said, on Apr. 20, it delivered a written notice to Cantor Fitzgerald, RBC Capital Markets to terminate sales agreement.
• What Avalo Therapeutics Does: Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases.

Check This Out: Top 5 Industrials Stocks That Could Lead To Your Biggest Gains In April

Don’t forget to check out our premarket coverage here